Radiocontrast nephrotoxicity is a common and imporreceptor antagonism.
ity is not clearly defined, an imbalance between vasodilatoxicity. Endothelin antagonists may reduce the renal hemodytory and vasoconstrictive factors has been proposed as namic abnormalities following radiocontrast administration. a mechanism for causing renal medullary ischemia [5] .
Methods. One hundred fifty-eight patients with chronic renal insufficiency [mean serum creatinine Ϯ SD ϭ 2.7 Ϯ 1.0 mg/dL Endothelin is an endogenous peptide with potent va-(242.3 to Ϯ 92.8 mol/L)] and undergoing cardiac angiography soconstrictor effects, including preferential reduction of were randomized to receive either a mixed endothelin A and intrarenal blood flow [6, 7] . In animals, significant in-B receptor antagonist, SB 290670, or placebo. All patients creases in both plasma and urinary endothelin levels received intravenous hydration with 0.45% saline before and have been observed during and after intravenous radioafter radiocontrast administration. Serum creatinine concencontrast administration [8] . Furthermore, endothelin retrations were measured at baseline, 24 hours, 48 hours, and 3 ceptor antagonists have been found to prevent renal to 5 days after radiocontrast administration. The primary end point was the mean change in serum creatinine concentration vasoconstriction in animal models of radiocontrast nephfrom baseline at 48 hours; the secondary end point was the rotoxicity [9, 10] . However, to our knowledge, there have incidence of radiocontrast nephrotoxicity, defined as an increase been no studies of these antagonists for the prevention in serum creatinine of Ն0.5 mg/dL (44 mol/L) or Ն 25% from of radiocontrast nephrotoxicity in humans. baseline within 48 hours of radiocontrast administration. SB 209670 [(1RS-2SR, 3RS)-3- (2-carboxymethoxy-4- Results. The mean increase in serum creatinine 48 hours methoxy-phenyl)-5-(prop-1-yloxy)indane-2-carboxylic after angiography was higher in the SB 209670 group [0.7 Ϯ acid; SmithKline Beecham Pharmaceuticals, King of Prus-0.7 mg/dL (63.5 Ϯ 58.6 mol/L)] than in the placebo group [0.4 Ϯ 0.6 mg/dL (33.6 Ϯ 55.1 mol/L), P ϭ 0.002]. The inci-sia, PA, USA] is a novel, nonpeptide-mixed endothelin dence of radiocontrast nephrotoxicity was also higher in the receptor A and B (ET A and ET B ) antagonist. In animals, SB 209670 group (56%) compared with placebo (29%, P ϭ infusion of SB 209670 prior to radiocontrast administra-0.002). This negative effect of SB 209670 was apparent in both tion resulted in a significant increase in renal blood flow diabetic and nondiabetic patients. Adverse effects, especially and attenuated the reduction in glomerular filtration rate hypotension or decreased blood pressure, were more common [10] . This multicenter, prospective, randomized study in the SB 209670 group. was performed to determine whether or not the adminis-
Conclusions.
In patients with chronic renal insufficiency who were undergoing cardiac angiography, endothelin receptor an-tration of SB 209670 prevents increases in serum creatitagonism with SB 209670 and intravenous hydration exacerbate nine concentration and reduces the incidence of radioradiocontrast nephrotoxicity compared with hydration alone. contrast nephrotoxicity in a group of patients at high risk for this complication while undergoing cardiac angiography. raphy with serum creatinine Ն2.0 mg/dL (176.8 mol/L) Study end points within 48 hours prior to radiocontrast administration
The primary end point of the study was the mean were eligible for the study. Exclusion criteria were a change in serum creatinine from baseline value at 48 supine blood pressure of Ͻ100/70 mm Hg or a heart rate hours after radiocontrast administration. The predefined of Ͼ100 beats per minute at baseline, acute renal failure, secondary end points were the incidence of radiocontrast chronic renal failure requiring dialysis, inability to adnephrotoxicity, peak serum creatinine level, and durahere to the hydration regimen, diuretic therapy within tion of hospitalization. Radiocontrast nephrotoxicity was 12 hours or during infusion of study drug, dopamine defined as a Ն0.5 mg/dL (44 mol/L) or Ն25% increase therapy within six hours or during infusion of study drug, in serum creatinine concentration from baseline within administration of nonsteroidal anti-inflammatory drugs 48 hours of radiocontrast administration. other than aspirin (Յ325 mg per day) within 24 hours of study drug, uncontrolled cardiac arrhythmia, hepatic Statistical analysis dysfunction, cerebrovascular accident within one week, Randomization was performed locally by means of and women of child-bearing potential. All patients resealed envelopes. A hospital pharmacist was designated ceived Ն50 ml of intra-arterial low osmolar radioconas the unblinded third party for preparation of the study trast. The indications for angiography and the choice drugs and random assignment of treatment. of low osmolar radiocontrast were determined by each A sample size of 172 patients (86 per treatment group) patient's cardiologist and were based on clinical needs.
was initially planned in order to detect a 0.5 mg/dL The protocol was approved by the institutional review (44 mol/L) difference in serum creatinine between SB board at each institution, and all patients gave written 209670 and placebo, assuming a standard deviation of informed consent. change in serum creatinine from baseline of 0.8 mg/dL (71 mol/L) for both treatment groups, with 90% power Study protocol and a two-tailed significance level of 0.05. The study design involved a double-blind random as-Data are reported as mean values Ϯ SD for continuous signment of patients to receive either SB 209670 (100 variables and as percentages for discrete variables. Cong/kg of ideal body weight over 10 min, followed by an tinuous variables were analyzed by two-tailed t-test and infusion of 1.0 g/kg per min) or placebo. This dose of discrete variables by the chi-square test or Fisher's exact SB 209670 was found to result in a steady-state plasma test. A P value of less than 0.05 was considered statisti-SB 209670 concentration of approximately 1200 ng/mL. cally significant. The percentage of patients with an in-In prior studies, this dose was the highest tolerated dose crease in serum creatinine of 0.5 mg/dL (44 mol/L) or in older or hypertensive patients and resulted in a modest Ն25% increase over baseline after radiocontrast adminreduction in blood pressure in patients with essential istration was evaluated by Cochran-Mantel-Haenszel hypertension (abstract; Am J Hypertens 11:171A, 1998). methodology with center as strata. The change in serum All patients received 0.45% saline intravenously at a rate creatinine concentration and peak serum creatinine conof 1 mL/kg of body weight per hour beginning 2 to 12 centration was analyzed by a general linear model. hours prior to and continuing for at least 12 hours after
The serum creatinine level at 48 hours after radioconradiocontrast administration.
trast administration, the change in serum creatinine at SB 209679 or placebo was begun 30 to 150 minutes 48 hours from baseline value, and the incidence of nephbefore radiocontrast administration and was infused for rotoxicity for each treatment group were compared sepa-12 hours; interventions for coronary artery disease were rately for diabetic versus nondiabetic patients. Standard postponed for 48 hours after radiocontrast administrat-test analyses were used in comparing the creatinine tion unless necessitated by refractory ischemia. Infusion values. Logistic regression was used for the comparison of the study drug was terminated early for the developof nephrotoxicity. ment of heart rate Ͼ130 beats per minute, hypotension
In order to assess the effects of treatment with SB not responsive to intravenous fluids (systolic blood pres-209670 and diabetes, four models were created for each sure Ͻ80 mm Hg or a decrease in systolic or diastolic end point. One model used the presence or absence of blood pressure Ͼ30 mm Hg), symptoms or signs of organ diabetes as the predictor, while another model used the hypoperfusion, need for protocol-prohibited medicatreatment group as the predictor in order to evaluate tions, or any other severe adverse effect. Vital signs were the univariable effects of these factors on the end points. measured at baseline, prior to initiation of study medica-
The third model assessed both diabetes and treatment tion, every 10 minutes for the first hour, every hour for group for any independent effect. The final model inthe next 11 hours, and then every 4 hours for 12 hours.
cluded diabetes, treatment group and the interaction of Serum creatinine measurements were performed at basediabetes and treatment to test for a differential treatment line and at 24 hours, 48 hours, and 3 to 5 days after the initiation of study medication. effect in diabetic versus nondiabetic patients. General increase in serum creatinine concentration and the inciout of 158 patients had serum creatinine measurements dence of radiocontrast nephrotoxicity were significantly available for the analysis of efficacy.
greater for the SB 209670 group compared with placebo Table 1 shows the baseline characteristics of the two (Table 3) . Furthermore, diabetic patients who received study groups; no significant differences were detected SB 209670 had an absolute increase in serum creatinine between the groups. The number of patients with diabeand an incidence of radiocontrast nephrotoxicity that tes mellitus or congestive heart failure was similar in both was significantly higher than nondiabetics who received groups, as was the number receiving calcium-channel SB 209670. When the relative increases in serum creatinine were antagonists before angiography. The volume of radioevaluated with respect to diabetic status, SB 209670 recontrast agent given in the two groups was also similar.
sulted in a 45% increase among diabetic patients com-Baseline serum creatinine concentrations were similar pared with a 43% increase among nondiabetic patients. for the two treatment groups (P ϭ 0.842). At 48 hours Logistic regression modeling of the interaction between after radiocontrast administration, there was a trend totreatment and diabetes on the end point of radiocontrast ward a higher mean serum creatinine concentration in nephrotoxicity demonstrated that the effect of SB 209670 the SB 209670 group compared with the placebo group on the incidence of radiocontrast nephrotoxicity was not [3.5 Ϯ 1.2 mg/dL (308.9 Ϯ 104.9 mol/L) vs. 3.1 Ϯ 1.2 statistically different in diabetic versus nondiabetic pamg/dL (277.1 Ϯ 105.2 mol/L), respectively, P ϭ 0.062]. tients (P ϭ 0.356). At three to five days follow-up after cardiac angiography, Adverse effects were more frequent in the SB 209670 there was no significant difference in the mean serum treatment group compared with placebo (Table 4 ). In creatinine concentration between patients treated with the SB 209670 group, nine (12%) patients were with-SB 209670 and those who received placebo [3.6 mg/dL drawn from the study during the 48-hour period after (315.4 mol/L) vs. 3.4 mg/dL (301.5 mol/L), respecradiocontrast administration because of adverse events tively, P ϭ 0.880]. The mean time to peak serum creaticompared with three (4%) patients in the placebo group. nine concentration was 57.1 hours in the SB 209670 group
In the SB 209670 treatment group, decreased blood presand 56.2 hours in the placebo group (P ϭ 0.910).
sure (either a transient decrease or hypotension as de-For the primary end point, the increase in serum creatifined earlier in this article) occurred in 14 (18%) patients; nine concentration was significantly greater at both 24 in the placebo group, these adverse effects occurred in eight (10%). Among the 14 out of 77 patients in the and 48 hours in the SB 209670 group than in the placebo SB 209670 treatment group who developed either frank vasoconstrictor action of endothelins in human blood hypotension or decreased blood pressure, the mean invessels [20] . The relative contribution of each subtype crease in serum creatinine concentration at 48 hours after to the vasopressor effects of endothelins is believed to radiocontrast administration was 0.5 Ϯ 0.5 mg/dL (42.8 Ϯ vary depending on the vascular bed in question. 42.1 mol/L), compared with 0.8 Ϯ 0.7 mg/dL (73.1 Ϯ Because of the potent effects of endothelins on renal 60.7 mol/L) in 63 out of 77 patients who did not experiblood flow [7] , endothelin receptor antagonists may offer ence this complication (P ϭ 0.080).
potential new therapies for renal diseases in which vasoconstriction may play a role. For example, ET A -selective and mixed antagonists have been shown to improve the DISCUSSION renal blood flow and glomerular filtration rate in animal Radiocontrast nephrotoxicity is a common cause of models of cyclosporine-induced renal failure [21, 22] . SB hospital-acquired renal failure and is a well-recognized 209670, a nonselective endothelin receptor antagonist, complication of cardiac angiography. Depending on the has been found in prior animal studies to increase renal definition of radiocontrast nephrotoxicity and the patient blood flow after radiocontrast administration [9] and population, the incidence has been reported to occur in 0 to 58% of patients after radiocontrast administration thus was evaluated in the present study for the preven- [11] [12] [13] [14] . Furthermore, patients who develop radiocontion of radiocontrast nephrotoxicity in patients undergotrast nephrotoxicity have a significantly higher mortality ing cardiac angiography. rate compared with patients who do not develop this In this study, the mean increase in serum creatinine complication, even after adjustment for differences in concentration was significantly higher in patients who comorbidity [4] . A number of therapies, particularly the received SB 209670 compared with those who received use of intravenous hydration [15], diuretic agents [15], placebo. Similarly, the incidence of radiocontrast nephand nonionic radiocontrast media [16, 17] , have been rotoxicity was not reduced by the use of SB 209670 in evaluated for reducing the risk of this complication. In patients with pre-existing renal dysfunction. In contrast, this study, we evaluated a novel endothelin receptor the incidence of radiocontrast nephrotoxicity at 48 hours antagonist in patients at high risk for developing radioafter radiocontrast administration was significantly higher contrast nephrotoxicity after cardiac angiography.
in patients who received SB 209670 compared with pa-Endothelins, a peptide family of closely related isotients who received placebo (56 vs. 29%, respectively). forms, act on two distinct subtypes of receptors called Importantly, the negative effect of SB 209670 was ap-ET A and ET B receptors [18, 19] . In the past, ET A recepparent in both diabetic and nondiabetic patients who tors were believed to mediate the vasoconstrictor effects received the endothelin receptor antagonist. Although of endothelins, whereas ET B receptors were thought to diabetic patients who were treated with SB 209670 had produce vasodilatory effects. However, both subtypes of receptors have recently been found to be involved in the a significantly higher increase in serum creatinine and increase renal blood flow and preserve the glomerular filtration rate after intravascular radiocontrast administration [25, 26] , yet clinical outcome measures, such as the incidence of radiocontrast nephrotoxicity, were not incidence of radiocontrast nephrotoxicity at 48 hours, the relative increase was similar for both end points evaluated. Low-dose dopamine infusion has also been observed to increase renal blood flow but was associated among diabetic and nondiabetic patients. The small number of nondiabetic patients may have contributed to this with a higher incidence of radiocontrast nephrotoxicity in diabetic patients [27, 28] . It has been hypothesized that lack of statistical significance for the effect of SB 209670, and modeling of the interaction of these two factors vasodilators may primarily affect renal cortical blood vessels, resulting in an intrarenal "steal" phenomenon, (treatment group and presence of diabetes) showed no significant difference for effect of SB 209670 in diabetic which worsens renal medullary ischemia [28] . Thus, despite beneficial effects on renal hemodynamics, the po-versus nondiabetic patients.
There are a number of possible reasons that SB 209670 tential role of vasodilator agents in reducing the risk of radiocontrast nephrotoxicity remains unproved. Our was not efficacious for reducing the incidence of radiocontrast nephrotoxicity. The present study involved pa-results further emphasize the discrepancy between surrogate markers of renal function, such as renal blood flow tients with significant chronic renal insufficiency before cardiac angiography [mean serum creatinine ϭ 2.7 Ϯ and glomerular filtration rate, and clinical outcome. Finally, the group of patients in our study who received 1.0 mg/dL (242.3 Ϯ 92.8 mol/L)], including 63% with diabetes mellitus. In this population, the response of intravenous saline and placebo had an incidence of radiocontrast nephrotoxicity of 29%. This rate is somewhat the renal vasculature to endothelin and thus endothelin receptor antagonism may be attenuated or abnormal.
higher than that reported in a recent study comparing intravenous saline alone to diuretic therapy plus saline, Although there was a higher incidence of hypotension in patients treated with SB 209670 and, consequently, which used the same definition and observed an 11% incidence of radiocontrast nephrotoxicity in the saline-possible renal medullary ischemia, the mean increase in serum creatinine for patients with this adverse effect was alone group [15] . However, the present study included patients with higher baseline serum creatinine concentra-less than for patients who did not have hypotension. Finally, at higher concentrations, SB 209670 has been tions and a higher percentage with diabetes mellitus. In addition, although the mean total duration of hydration found to block ET B receptors [23], thus inhibiting any potential vasodilatory effect of endothelin and possibly in our placebo group was 24 hours, the duration of hydration before radiocontrast administration was more vari-increasing plasma levels of endothelin [24] .
Two broader questions are also raised by the results able compared with the prior study [15] . At present, intravenous saline remains the most effective measure of this study: (1) the actual role of endothelin in the pathogenesis of radiocontrast nephrotoxicity; and (2) the for reducing the risk of radiocontrast nephrotoxicity, although the optimal amount of hydration is not known. potential benefit of any vasodilator therapy for reducing the risk of this complication. In animal models of radio-In conclusion, the use of an intravenous mixed endothelin receptor antagonist did not reduce the risk of contrast nephrotoxicity, endothelin receptor antagonists increased renal blood flow and reduced renal vascular radiocontrast nephrotoxicity in patients with significant pre-existing renal dysfunction undergoing cardiac angi-resistance after radiocontrast administration only when the production of renal prostaglandin was concomitantly ography. Rather, patients treated with this agent and intravenous hydration had a significantly higher inci-inhibited [9, 10] . Thus, the interactions of multiple vasodilatory and vasoconstrictor influences likely determine dence of radiocontrast nephrotoxicity compared with patients treated with intravenous hydration alone. In the whether radiocontrast nephrotoxicity occurs. Furthermore, the present study evaluated a mixed ET A and ET B future, patients treated with this novel class of therapeutic agents may require close observation for the develop-receptor antagonist, and it is unknown whether selective ET A blockade may be beneficial in preventing radiocon-ment of nephrotoxicity after radiocontrast administration. Further studies of therapies for the prevention of trast nephrotoxicity. Despite these considerations, the
